ライフサイエンスコーパス: forehead

1 ent's headache and the mass on the patient's forehead.

2 blindness caused by filler injected into the forehead.

3 gs, and a thermoluminescent dosimeter on the forehead.

4 roencephalographic (EEG) recordings from the forehead.

5 els in the periorbital area, upper face, and forehead.

6 hand quickly toward their face and tap their forehead.

7 rtelorism or broadening of the nasal root or forehead.

8 electrode on the temple and the earth on the forehead.

9 ip of the nose and another at the top of the forehead.

10 93 from blood, 92 from conjunctiva, 54 from forehead, 105 from mouth, 17 from the rectum, one from s

11 station, including score of pigment spots on forehead (12.5% more spots per increase of IQR, P-value

12 ed site) and facultative pigmentation on the forehead (a sun-exposed site) and calculated a sun expos

13 asures constitutive pigmentation) and on the forehead (a sun-exposed site) using reflectometry.

14 ese include a globular braincase, a vertical forehead, a dimunitive browridge, a canine fossa and a p

15 2 U of abobotulinumtoxinA on one side of the forehead and 2 U of onabotulinumtoxinA on the other side

16 cus was the most common genus present on the forehead and behind the ear.

17 eatment of facial furrows, new techniques in forehead and brow suspension, the suborbicularis oculi f

18 hypertelorism, malformations of the nose and forehead and clefting of the facial midline.

19 Optical probes were placed on the forehead and EEG electrodes on the scalp.

20 ars in good health and with moderate dynamic forehead and glabellar wrinkles.

21 amic therapy for the treatment of AKs on the forehead and scalp.

22 challenges: cold application to the hand or forehead, and a Valsalva maneuver.

23 (>/=20 cm) involving 80% of the scalp, left forehead, and left cheek, with no evidence of metastasis

24 irreversible blindness when injected in the forehead, and this possible adverse effect is not typica

25 ed microretrognathia, flat midface, receding forehead, and wide fontanelles.

26 rozygous for mutations of c-kit have a white forehead blaze and a white ventral spot, leading these m

27 pressing transgenic mice display a prominent forehead blaze and a white ventral spot.

28 ansgenic mice (hSCF220) display a pronounced forehead blaze, with additional white spots over the cer

29 cial fillers are not approved for use in the forehead, but off-label use for enhancement in this regi

30 d mass protruding from the right side of her forehead, but there were no other notable abnormalities.

31 ght of as the syndrome of blunt force to the forehead causing visual loss, but iatrogenic injury is i

32 Intradermal forehead challenge infection with 107 metacyclic L. amaz

33 ographic sites were studied in each subject: forehead, cheek, inner and outer forearm surfaces, lower

34 an failure (POF) in women, as well as eyelid/forehead dysmorphology in both sexes (the 'blepharophimo

35 ial autonomic features included rhinorrhoea, forehead/facial sweating, itching eye, eyelid oedema, se

36 al autonomic features include eyelid oedema, forehead/facial sweating, sense of aural fullness and pe

37 skin, lips, and facial rhytids (ie, overall, forehead, glabella, lateral periorbital area, lips, and

38 eyelid edema (5%), blepharoptosis (5%), and forehead hyperemia (2%).

39 Periocular crow's feet lines and horizontal forehead lines are also amenable to treatment with the b

40 otonumeric scales (Griffiths scale, Allergan forehead lines scale, melomental folds scale, and crow's

41 ffiths scale: chi2 = 0.01, P = .93; Allergan forehead lines scale: chi2 = 0.18, P = .67; melomental f

42 ffiths scale: chi2 = 1.39, P = .24; Allergan forehead lines scale: chi2 = 0.64, P = .43; melomental f

43 ffiths scale: chi2 = 3.11, P = .08; Allergan forehead lines scale: chi2 = 0.89, P = .34; melomental f

44 ps with low exposure in the first trimester (forehead), moderate to high exposure in the first trimes

45 ed and tested axillary, blood, conjunctival, forehead, mouth, rectal, semen, urine, and vaginal speci

46 s taken from the axilla, blood, conjunctiva, forehead, mouth, rectum, and urine of the same participa

47 The screening sites included the forehead, nostrils, buccal mucosa, axilla, antecubital f

48 ollected by swiping a glass slide across the forehead of consenting adults.

49 issue-like phantoms, and measurements on the forehead of three human subjects.

50 ly observed for Staphylococcus aureus on the foreheads of seropositive individuals.

51 Samples of RSSC were collected from the foreheads of type-1 diabetic (n = 55) and non-diabetic (

52 anted after tumour excision under paramedian forehead or nasolabial flaps, as in standard reconstruct

53 (grade 2-4 kidney cysts or angiomyolipomas, forehead plaques, retinal hamartomas, and liver angiomyo

54 d dysmorphic facial appearance with receding forehead, prominent nose, and micrognathia.

55 ugator supercilii (frowning), and frontalis (forehead raising).

56 tal plane with the use of a bite plate and a forehead rest.

57 on 5 of the 6 rhytids scales (exception was forehead rhytids) (range, -0.28 to -0.65; P = .03 to <.0

58 ng a tone conditioned stimulus and a midline forehead tap as an unconditioned stimulus.

59 The KTER extinguished when the forehead tap did not reinforce it.

60 ry eyeblinks which were initiated before the forehead tap.

61 ry eyeblinks which were initiated before the forehead tap.

62 ture and technology, from the furrows on our foreheads to crinkly plant leaves, from ripples on plast

63 d toe webs with separate rayon swabs and the forehead, upper arm, and thigh with separate sponges.

64 nal cerebral oxygenation on the left lateral forehead using near-infrared spectroscopy for the first

65 38) spatial incongruence of touch (cheek vs. forehead) was used as a control condition instead of tem

66 features of brachycephaly; a prominent high forehead with synophrys or striking full and broad eyebr